US Cancer Association Adds Blood Test to Colorectal Cancer Screening Recommendations

The American Cancer Society has recently announced that it will include the FDA-approved Guardant Health Shield blood test in its recommended screening options for colorectal cancer in the United States. This decision comes at a time when the incidence of colorectal cancer among young adults is on the rise. According to the latest cancer statistics, the incidence of colorectal cancer among young adults in the United States has been increasing in recent years, particularly among those without a family history or other known risk factors. Thus, the American Cancer Society's update on screening methods is of significant importance.

The American Cancer Society is a national non-profit organization dedicated to eliminating cancer. The organization publishes several journals, including Cancer, Clinical Cancer Journal, and Cancer Cell Pathology, providing crucial information and guidance for medical research and clinical practice. As a leading cancer research and prevention organization, the American Cancer Society's recommendations carry significant influence in the medical community and the public. Through its continuously updated and improved screening guidelines, the organization aims to increase the early detection and treatment rates of cancer, ultimately improving patient outcomes and quality of life.

Guardant Health Shield blood test is a liquid biopsy-based technology that detects colorectal cancer by analyzing circulating tumor DNA in the blood. This method is more convenient and has higher patient compliance rates compared to traditional screening methods, such as colonoscopy. Through this test, doctors can detect colorectal cancer at an earlier stage, providing timely treatment and intervention. The American Cancer Society's recommendation indicates that the organization recognizes the value and potential of this new technology in colorectal cancer screening.

For public health in the United States, particularly among young adults, colorectal cancer screening and early detection are of critical importance. By placing greater emphasis on colorectal cancer screening and adopting new detection technologies, the medical community and the public can work together to reduce the incidence and mortality rates of colorectal cancer. The American Cancer Society's efforts and recommendations provide important guidance and support for this initiative.

The American Cancer Society's update on colorectal cancer screening also reflects the ongoing progress in medical research and technology. Through the integration of the latest research findings and technological developments, the medical community can continuously improve cancer early detection and treatment outcomes. This progress is not only significant for public health in the United States but also provides valuable experience and insight for global cancer prevention and treatment.

For Taiwan, this event highlights the importance of understanding the international medical community's emphasis on cancer screening and early detection. As a region with relatively advanced medical technology and research, Taiwan can learn from the American Cancer Society's efforts and recommendations to enhance its emphasis on cancer screening and prevention. Taiwan can also collaborate with the international medical community to promote cancer research and technological development, making a valuable contribution to global cancer prevention and treatment.